The activity of motor cortical inhibitory circuits was studied with paired transcranial magnetic stimuli in 16 patients with Parkinson's disease 'off' therapy, five patients 'off' and 'on' therapy, and 11 normal subjects. Paired 
Introduction
Over the past few years, transcranial magnetic stimulation has become a valuable tool for the study of the excitability of motor pathways in normal subjects as well as in patients with basal ganglia abnormalities. The basal ganglia, being tightly connected with motor cortices through the so-called 'motor circuit', influence thalamo-cortical projections and regulate cortical activity (Alexander and Crutcher, 1990) .
Various attempts have been made to detect alterations in cortical excitability in Parkinson's disease, including measurement of the threshold of muscle potentials evoked by magnetic stimulation, and of the silent period following evoked potentials. However, threshold measurements have produced inconsistent results. Some authors have found a decrease (Cantello et al., 1991) , others an increase (Davey et al, 1991) , and others no change VallsSole et al., 1994; Ridding et al., 1995) in the threshold of parkinsonian patients compared with normal subjects. The silent period evoked by transcranial magnetic stimulation,
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having been attributed, at least in its latter part, to the activity of intracortical inhibitory systems (Fuhr etal., 1991; Inghilleri et al., 1993; Roick et al., 1993; Wilson et al., 1993) , has proved to be more useful as an indicator of changes in cortical excitability. Several authors have reported that the cortical silent period is shorter in Parkinson's disease (Cantello et al., 1991; Valls-Sole" et al., 1994) , and that it can be prolonged by dopaminergic therapy Ridding et al., 1995) , thus confirming the important role of the basal ganglia in the modulation of cortical excitability.
A different method of examining cortical excitability is to use paired magnetic shocks delivered in a conditioning-test protocol at varying interstimulus intervals. Studies in normal subjects (Claus etal, 1992; Valls-Sole" etal., 1992; Inghilleri et al., 1993; Kujirai et al., 1993) have shown that, according to the intensity of stimulation used or whether the study is performed at rest or in contraction, excitatory or inhibitory *   22  20  27  19  35  14  18  22  18  20  35  19  22  42  17  33  21  37  20  15   Modified Hoehn and  Yahr scale   4  3  3  2  3  2  2  2  2  2  4  2  3  4 2.5 4 2 4 2.5 2
•The score refers only to the motor section of the scale.
effects may be obtained. Using a conditioning stimulus of subthreshold intensity and a suprathreshold test stimulus, Kujirai et al. (1993) found an inhibition of the test response at intervals below 5 ms in relaxed as well as in active muscle, and provided evidence that this inhibition is the result of activity in intracortical inhibitory circuits. Longer interstimulus intervals have been studied in active muscle by Claus et al. (1992) and by Inghilleri et al. (1993) . Claus et al. (1992) , with both conditioning and test stimuli slightly suprathreshold, found strong inhibition from 30 to 200 ms with a maximum at 80 ms. Inghilleri et al. (1993) , using higher intensity of stimulation, noticed complete suppression of the test response at 100 ms and strong inhibition at 200 ms.
The aim of the present study was to examine the activity of intracortical inhibitory circuits in patients with Parkinson's disease with this new technique, and to compare the behaviour of the response to paired stimuli with that of the silent period in order to detect possible correlations.
Material and methods Subjects
Twenty patients with Parkinson's disease (mean age±SEM 64.5 ±2.5; range 34-78 years) and 11 normal subjects (mean age±SEM 60.5±3.7; range 39-74 years) participated in the study. Informed consent was obtained from all participants and the study was approved by the local ethical committee. Clinical evaluation was performed using the motor section of the Unified Parkinson's Disease Rating Scale and a modified Hoehn and Yahr scale. Clinical data of patients are listed in Table 1 . Before studies began, patients had been off therapy for at least 12 h. Five patients were studied before and 40 min after an oral dose of 251.2 mg of L-dopa methylester (a fast-acting formulation produced by Chiesi Farmaceutici, Parma, Italy) when they showed a marked clinical improvement. In order to block peripheral dopamine activity, oral carbidopa (50 mg) was given 30 min before the L-dopa.
Stimulation technique
Subjects were seated in a comfortable chair. Transcranial stimulation was performed with Magstim D200 magnetic stimulators and a large round coil with an outer diameter of 14 cm (maximum magnetic field 2.5 Tesla). Paired stimuli were delivered using two magnetic stimulators connected to the same stimulating coil through a Bistim module. To activate the left hemisphere predominantly, both stimuli were applied over the vertex with the current flowing in an anticlockwise direction when viewed from above (Rothwell et al., 1991) . In order to investigate the time course of the effects under study, we used a conditioning-test design with paired stimuli given at short (3, 5, 7, 10, 15, 20 ms) and long (100,150,200,250 ms) intervals. Stimuli were delivered in four blocks of trials. A block consisted of eight trials each of three or four conditions: the response to a test shock given alone, and the response to the same shock when conditioned by a prior stimulus at different conditioning-test intervals. Within each block, paired shocks at different intervals were randomly intermixed and given every 5 s. In order to obtain an inhibitory effect, the intensity of the conditioning stimulus was subthreshold (80% of motor threshold) with short (see Kujirai et al, 1993) , and suprathreshold (150% of motor threshold) with long {see Valls-Sole et al., 1992; Inghilleri et al., 1993) interstimulus intervals. The test stimulus was always delivered at 125% of motor threshold. Motor threshold was defined as the lowest stimulus intensity capable of evoking a clearly distinguishable muscle evoked potential (MEP) with an amplitude of 200 ^V or higher in at least three consecutive trials. Since patients with Parkinson's disease find it difficult to relax, determination of threshold and all paired stimulus experiments were performed during slight voluntary activation at -20% of maximum voluntary electromyogram (EMG) of the muscle under examination. Audio-visual feedback of the level of activation was provided by a Tektronix oscilloscope and a loudspeaker. Subjects who presented excessive activation or who were not able to maintain a constant EMG level throughout the experiment were excluded. The cortical silent period following a single magnetic shock given at 150% of motor threshold was determined while the subjects performed maximum voluntary contraction.
Recording technique
Electromyogram recordings were made from the first dorsal interosseous muscle using a pair of surface electrodes.
Responses were amplified and filtered (Digitimer D 160) with a time constant of 3 ms and a low pass filter set a 1 kHz, recorded onto a personal computer through a 1401 laboratory interface (Cambridge Electronic Design) and analysed off-line. The amplitude of the MEP was measured peak-to-peak and expressed as a percentage of an unconditioned control response (see Kujirai et al., 1993) . For each condition, eight trials were collected and averaged. The amount of tonic activation was measured calculating the level of background EMG (average of eight rectified traces) during the 10 ms immediately preceding the test stimulus at the 150 ms and 200 ms intervals, and expressed as a percentage of the average background activity measured during the 100 ms preceding the control stimulus. We decided to use a time base of only 10 ms before the test stimulus in order to avoid including part of the silent period. The duration of the cortical silent period was measured from the end of the MEP to the return of continuous EMG activity; each value represents the average of eight rectified traces.
Statistical analysis
All results are expressed as means ±1 SEM. Statistical evaluation of the differences between groups was carried out separately for short and long intervals using the one-way ANOVA. In the case of overall group significance, single interval comparisons were made. Results of patients 'off' and 'on' therapy were compared with the repeated-measures ANOVA. Correlations between test results and clinical features of patients were evaluated with a linear regression and a correlation test. P values <0.05 were considered to indicate significance.
Results

Cortical silent period
The silent period after transcranial magnetic stimulation was shorter in patients (129 ±10.5 ms) compared with normal subjects (144±14.6 ms). However, this difference was not statistically significant.
Threshold
The threshold for obtaining EMG responses was not significantly different in normal subjects and patients with Parkinson's disease, neither in the total group (normal subjects, 46.2±2.8%; patients, 48.1 ±2.2% of maximum stimulator output) nor in subjects with silent periods shorter than 130 ms (normal subjects, 42.6±5.1%, n = 5; patients, 50.0±3.4%, n = 8).
Muscle evoked potential amplitude
In the total group, there was no difference between normal subjects and patients regarding the mean amplitude of conditioning (150% of threshold: controls, 4.2 ±0.8 mV; patients, 4.5±0.5 mV) and control responses (125% of threshold, controls, 2.4±0.6 mV; patients, 2.4±0.3 mV). Also in the subgroup with silent periods shorter than 130 ms, conditioning as well as control responses were not significantly different in normal subjects (conditioning MEP, 4.9±1.4 mV; control MEP, 2.4±0.9 mV) compared with parkinsonian patients (conditioning MEP, 3.5±0.7 mV; control MEP, 1.9 ±0.4 mV).
Background EMG
The average level of background EMG activity during the time period immediately preceding the test stimulus as related to the average level of background activity preceding the control stimulus was similar in normal subjects (150 ms, 42.3±10%; 200 ms, 84.2±21%) and patients with Parkinson's disease (150 ms, 45.8±9.7%; 200 ms, 78.3±10.4%).
Paired stimuli Short interstimulus intervals
In normal subjects (n = 11), the test response was significantly inhibited when it was preceded by a conditioning stimulus at an interval of 3 ms (51.9±7.6% of the control response). Although less marked, inhibition of the test response was also present at intervals of 5 ms (81.2±12.5%), 7 ms (86.3±4.7%), 10 ms (89.6±6.8%), 15 ms (94.9± 13.5%) and 20 ms (72.0±10.8%). In patients (n = 16), the test response was significantly inhibited by the conditioning stimulus at 3 ms (44.7±7.7%) as well as at 5 ms (79.1± 8.7%). At intervals between 7 and 15 ms, a slight facilitation of the test response could be observed (105.3±8.3% at 7 ms; 106.7±ll% at 10 ms; 112.3±10.3% at 15 ms). At 20 ms, the test response was again slightly inhibited (88.7±11.5% of the control response). The differences between patients and control subjects at intervals from 3 to 20 ms were not significant (Fig. 1) . 
Long interstimulus intervals
In normal subjects {n = 11), the test response was significantly inhibited at 100 and 150 ms (100 ms, 16.5±12.3%; 150 ms, 45.4±18.2%). At 200 ms, inhibition was still present but no longer significant (76.5±18.7%). In patients (n = 16), test responses were more inhibited (100 ms, 2.8±2.0%; 150 ms, 11.5±4.3%; 200 ms, 43.4±8.1%) compared with normal subjects, and the difference was statistically significant at interstimulus intervals of 150 as well as 200 ms (P < 0.05). Figure 2 shows the behaviour of conditioning and test responses in one representative patient and one control subject; total group values are illustrated in Fig. 3 .
At the 100 ms interval, a test response was present in 27.3% of normal subjects and in 12.5% of patients, at 150 ms in 45.5% of controls and in 37.5% of patients, and at 200 ms in 90.9% of controls and in 81.2% of patients. Considering only the subjects who presented a test response, its amplitude at 100 ms was 60.7±3.8% of the control response in normal subjects and 22.7±2.9% in patients, at the 150 ms interval it reached 99.8±21.5% in controls and 30.8±5.3% in patients, and at 200 ms the amplitude of the test response was 84.1 ± 18.9 in controls and 53.4±7.5 in patients.
To analyse the data further and in order to reduce intragroup variability, we have divided controls as well as patients into two subgroups of approximately equal size along the mean value of duration of the silent period: one group comprising all subjects with a silent period shorter than 130 ms (controls, 99.4±10.2 ms; patients, 94.4±8.7 ms), and the other group including all subjects with a silent period longer than 130 ms (controls, 181.2±10.3 ms; patients, 163.3±7.8 ms). In the first group, the difference between patients and normal subjects was even more evident at 150 ms (controls, 96.4 ±24.9% of the control response, n = 5; patients, 19.8±6.9%, n = 8) (P < 0.01) as well as at 200 ms (controls, 113.0±29.9%, n = 5; patients, 38.8± 12.4%, n = 8; P = 0.01) (Fig. 4) . In the second group, the test response was inhibited in patients and controls to a similar extent (controls, 2.9±2.9% at 150 ms; 46.1 ±16.8% at 200 ms, n = 6; patients, 3.3±3.3% at 150 ms, 48.0±11.0% at 200 ms, n = 8), due to the fact that most test stimuli were given before the end of the silent period.
To make sure that the silent period had ended in all subjects studied, we also examined an interstimulus interval of 250 ms in a subgroup of seven patients (mean silent period 137 ±19.4 ms) and seven controls (mean silent period 139 ±20.7 ms). In normal subjects, the test response was facilitated (139.9±23.0%), while it was still inhibited in patients (57.8±10.8%). This difference was also statistically significant (P<0.01).
Effect of L-dopa
The effect of L-dopa on the inhibition seen at interstimulus intervals of 150 and 200 ms was studied in a second group of five randomly selected patients. When patients were 'off' therapy, the amplitude of the test response was 28.6± 13.0% at 150 ms and 71.1 ±13.0% at 200 ms. 'On' therapy, the amplitude of the test response increased markedly (150 ms, 53.5±13.1%; 200 ms, 116.0±8.9%). The difference between 'off' and 'on' states was significant for overall groups (P = 0.01, paired data).
Correlation with clinical features
Although there was an overall correlation of test results at long intervals in patients with parkinsonian symptomatology, as was also evident from the improvement after intake of L-dopa, no significant correlation between the amount of inhibition and total Hoehn and Yahr or Unified Parkinson's Disease Rating Scale scores or single features such as rigidity or bradikinesia could be found.
Discussion
In normal subjects, the study of the excitability of motor cortex with paired magnetic stimuli has provided different results according to the intensity of stimulation used or whether the experiments were performed at rest or during contraction.
Previous studies with subthreshold or threshold conditioning stimuli delivered at short interstimulus intervals (Claus et al, 1992; Kujirai et al., 1993) have provided evidence for an inhibition of the test response at intervals up to 5 ms in both relaxed and active muscle, which was, however, more pronounced in the relaxed state. With interstimulus intervals of 10-15 ms, slight facilitation could be observed at rest and no variation in active muscle. The results obtained in the present study with short interstimulus intervals confirm the findings of these authors.
In patients with Parkinson's disease, the suppression of the test response by the conditioning stimulus at these intervals was not statistically different from that of normal subjects, suggesting that cortical excitability tested during voluntary activation and with subthreshold conditioning stimuli is not significantly abnormal in patients with Parkinson's disease. These results are in apparent contrast with recent findings of Ridding et al. (1995) , who have studied patients with Parkinson's disease with the paired stimulus technique and similar intensity of stimulation. They performed the experiments at rest and found a significant decrease in the amount of suppression of the test response at short (1-5 ms) interstimulus intervals in patients relative to their controls. The authors interpreted these results as a decrease in cortico-cortical inhibition in Parkinson's disease. In their opinion, the possibility that these changes were due to modifications of spinal excitability was excluded since the utilization of a subthreshold (threshold determined in the active state) shock in a relaxed subject would rule out the possibility that the conditioning shock produced a descending corticospinal volley. However, the experimental paradigm used in the present study differs from that of Ridding et al. (1995) , because our study was done during contraction and we did not use exactly the same interstimulus intervals. Also, differences regarding type and severity of Parkinson's disease affecting the patients studied may explain, at least in part, the difference observed. The rationale of performing the study in contraction was that patients with Parkinson's disease have difficulty in relaxing completely the muscle under examination (Berardelli et al., 1983) . Thus, examining both patients and normal subjects in contraction would make for a fairer comparison. Secondly, we wanted to compare the behaviour of the response to paired stimuli with that of the silent period, and therefore it was essential to perform the study during voluntary activation of the muscle.
How can we reconcile our findings with those of Ridding et al. (1995) ? Kujirai et al. (1993) have found that paired pulse inhibition with subthreshold conditioning stimuli is reduced when subjects are active compared with rest, and they suggested that this was likely to be caused by a reduction in the excitability of cortical inhibitory circuits. A change in the excitability of motor cortex could therefore be masked when patients with Parkinson's disease perform a voluntary contraction, i.e. the motor cortex in Parkinson's disease would be hyperexcitable at rest, and the difference with normal subjects would disappear during contraction. This suggestion is supported by recent observations of Valls-Sole' et al. (1994) , who studied the facilitation of motor evoked potentials by increasing the stimulus intensity and the degree of voluntary activation of the target muscle in patients with Parkinson's disease. Compared with normal subjects, they found an enhancement of excitability at rest and reduced facilitation during voluntary muscle activation. The excitability of motor cortex in Parkinson's disease at rest might therefore resemble the excitability seen in normal subjects when they exert a slight voluntary contraction.
The results obtained in the present study with longer interstimulus intervals (100-250 ms) in normal subjects confirm previous findings reported by various authors (Claus et al., 1992; Valls-Sole et al., 1992; Inghilleri et al., 1993) in showing that there is a period of absolute inhibition corresponding in length to the cortical silent period, followed by a period of partial recovery of the muscle potential of variable duration and eventually by a period of facilitation.
The mechanisms responsible for the inhibition seen at long interstimulus intervals are unlikely to be due to segmental mechanisms. Single motor neuron studies have demonstrated that the refractoriness of spinal motor neurons after magnetic stimulation lasts only for -50 ms (Boniface etal., 1991) . In the study of Inghilleri et al. (1990) , examining motor potentials evoked by paired supramaximal electrical cortical stimuli, we have shown that during contraction, the test response was strongly suppressed at the 20 ms interval, and recovered at intervals of 100 ms. We have proposed that several mechanisms might be responsible for this phenomenon, including recurrent inhibition by the Renshaw cell system (Baldissera et al, 1981) , after-hyperpolarization potential (Hultborn et al, 1979) and cortico-spinal inhibitory inputs (Lemon et al., 1987) . Since magnetic stimulation either acts directly at the initial segment of the corticospinal neuron or trans-synaptically upon the same neuron Rothwell et al, 1991; Burke et al, 1993; Baker etal, 1994) , intracortical inhibitory systems influencing these neurons would affect the threshold at which they would be excited by transcranial magnetic stimulation, and it is probable that this explains the inhibition seen with long interstimulus intervals.
With interstimulus intervals from 150-250 ms, we have seen that the test response was significantly more inhibited in patients with Parkinson's disease compared with normal subjects. This effect has been observed independently from the duration of the silent period, as shown also by the fact that the difference was still significant at an interstimulus interval of 250 ms, when the silent period had ended in all subjects studied. Several mechanisms might explain this finding. If, in the patients, the size of the conditioning MEP was larger than in normal subjects, this could result in more suppression of the test response. Indeed, the size of the MEP can be larger in Parkinson's disease patients than in normal subjects (Valls-Sol6 et al, 1994) . However, this mechanism can be excluded, because in the subjects studied by us, the size of conditioning as well as control MEPs was similar in patients and in normal subjects. Moreover, in the subgroup of patients and controls with silent periods shorter than 130 ms, the conditioning MEP was smaller in patients relative to their controls. There was also no significant difference in the average EMG background activity immediately preceding the test stimulus, and no significant rebound could be observed. Neither can the inhibition be explained with a change at segmental level because, as discussed before, segmental mechanisms do not operate at these intervals. The mechanisms responsible for the increased inhibition present in Parkinson's disease are therefore likely to be related to changes at cortical level.
Several authors have reported a significant shortening of the silent period in Parkinson's disease (Cantello et al, 1991; Priori et al, 1994; Valls-Sole", 1994) . In the group of patients studied by us, we have found only a slight shortening of the silent period. However, this difference is not surprising since it has been demonstrated that abnormalities of the silent period in Parkinson's disease are more evident when magnetic stimulation is performed at high intensity (Cantello et al, 1991; Valls-Sold et al., 1994) and when patients are compared in the 'on' and 'off' conditions Ridding et al, 1995) . Also, it has been observed that the duration of the silent period varies according to the muscle studied (Roick et al, 1993) . We have previously explained the shorter duration of the cortical silent period in parkinsonian patients on the basis of the primate model of basal ganglia functioning proposed by DeLong (1990) . According to this model, a reduction in the facilitating effect of the trans-thalamic motor circuit upon the motor cortices would produce decreased excitation of cortical inhibitory interneurons and consequently a shorter silent period .
To see whether the inhibition seen with paired pulse stimuli and the silent period after single magnetic stimuli share similar physiological mechanisms, we have compared the behaviour of these inhibitory phenomena using similar experimental paradigms. The duration of the silent period and the inhibition seen at long interstimulus intervals, at first glance, seem comparable with each other. In all except two normal subjects as well as in all of the patients, when tested with the paired stimulation paradigm at time intervals less than the duration of the silent period, the test response was completely inhibited. This would be compatible with the hypothesis of a similar physiological mechanism being responsible for the silent period and for the suppression of the second response after paired magnetic stimuli. On the other hand, the test response at long interstimulus intervals was more inhibited in patients with Parkinson's disease than in normal subjects. This appears to be in contrast with the finding of a shortening of the silent period. However, since the muscle potential evoked by transcranial stimuli is the result of a variety of excitatory and inhibitory inputs to cortical motor neurons, it may well be that different subsets of interneurons are involved in the production of the cortical silent period, representing an interruption of voluntary motor activity, and the inhibition of the response to a second magnetic stimulus occurring after the end of the silent period. With reference to the model of basal ganglia functioning proposed by DeLong (1990) and in line with recent results obtained by Valls-Sole et al. (1994) , the diminuition of thalamic drive upon the motor cortices in Parkinson's disease might result in a flattening of the excitability curve of the cortical motor neuron pool in the sense of a facilitation of tonic activity combined with a defect in producing the ultimate increase in excitability required for the execution of rapid movements.
Several neurotransmitters may be involved in the period of inhibition seen at short and long interstimulus intervals. Gamma-aminobutyric acid (GABA) has prolonged inhibitory effects that may last for 200 ms or more (McCormick, 1992) , and it is therefore likely that the release of GABA accompanies the inhibition of the test response. In the group of patients studied by us 'off and 'on' therapy we have observed a significant improvement of the response at long intervals after the intake of L-dopa. As already suggested for the silent period , the positive effect of L-dopa on the behaviour of the test response is probably due to modulation of GABAergic transmission at basal ganglia level.
In conclusion, we may speculate that the abnormal output from the basal ganglia onto the motor cortices in Parkinson's disease produces changes in the activity of a number of cortical inhibitory and excitatory interneurons, and that in parkinsonian patients there is a predominance of inhibitory effects. These may be relevant for the pathophysiology of the slowness of movement characteristic of Parkinson's disease.
